Nordic Nanovector ASA: Results for the Third Quarter 2020
The Pharma Data
NOVEMBER 18, 2020
These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME.
40 
Let's personalize your content